Clinical Trials Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Jul 21, 2024; 30(27): 3304-3313
Published online Jul 21, 2024. doi: 10.3748/wjg.v30.i27.3304
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flowchart of the clinical trial. VAT: Vonoprazan-amoxicillin dual therapy; BQT: Bismuth quadruple therapy; ITT: Intention-to-treat; PP: Per-protocol.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Intention-to-treat and per-protocol analyses of Helicobacterpylori eradication rates attained by bismuth quadruple therapy, Vonoprazan-amoxicillin dual therapy-10 and Vonoprazan-amoxicillin dual therapy-14. There were statistically significant differences in the eradication rates among the three regimens. VAT: Vonoprazan-amoxicillin dual therapy; BQT: Bismuth quadruple therapy; ITT: Intention-to-treat; PP: Per-protocol; 95%CI: 95% confidence interval.
  • Citation: Huang XP, Liu YJ, Lin SW, Shao YF, Qiu F, Qiu QW, Xu ZK, Chen JX, Chen LH, Lin ZQ, Dai WH, Zhang MQ, Jiang Q, Xiao ZQ, Cheng XX, Zhang XF, You WB, Chen W, Li LQ, Lin WX, Wang YF, Lai FJ, Chen LQ, Huang ZH, Zheng WQ, Wei JQ, Lin ZH. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study. World J Gastroenterol 2024; 30(27): 3304-3313
  • URL: https://www.wjgnet.com/1007-9327/full/v30/i27/3304.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v30.i27.3304